First in Man Study Investigating the Biodistribution, the Safety and Optimal Recommended Dose of a New Radiolabelled Monoclonal Antibody Targeting Frizzled Homolog 10 (FZD10) in Patients With Relapsed or Refractory Non Resectable Synovial Sarcomas
Latest Information Update: 07 Nov 2021
At a glance
- Drugs OTSA 101-Y 90 (Primary)
- Indications Synovial sarcoma
- Focus Adverse reactions; First in man; Pharmacokinetics
- Acronyms SYNFRIZZ
- 06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
- 23 Mar 2016 Results published in OncoTherapy media release.
- 22 Feb 2016 Status changed from active, no longer recruiting to completed, as reported by OncoTherapy media release.